2014 Archive:
ASX Announcements and News Releases

12/02/2014

Half Year Results announcement for 2013/14

CSL Limited (ASX:CSL) today announced a net profit after tax (NPAT) of US$646 million for the six months ended 31 December 2013, up US$21 million or 3% on a reported basis when compared to the prior comparable period (PCP). The result included a one-off U.S. antitrust class action litigation settlement of US$64 million, or US$39 million after tax.

09/05/2014

CSL Opens Australian Biotechnology Manufacturing Facility

CSL Limited today officially opened the CSL Behring Biotechnology Manufacturing Facility in Broadmeadows, Melbourne.

11/06/2014

International Medical Journal Publishes bioCSL's Fluvax® Investigation Findings

The findings of bioCSL's multi-year investigation into the cause of the unexpected adverse events associated with its Fluvax® influenza vaccine in 2010 were today published in two separate papers in the peer-reviewed journal Vaccine.

21/07/2014

bioCSL partners with Immucor to distribute global market-leading transfusion testing technology

bioCSL today announced that it has commenced distribution of Immucor Corporation's global market-leading "Capture®" technology platform and reagents in Australia and New Zealand. Capture® is an advanced antibody detection technology used in the cross-matching of blood used for transfusion.

13/08/2014

Full Year Results announcement for 2013/14

CSL Limited (ASX:CSL; USOTC:CSLLY) today announced a net profit after tax (NPAT) of US$1,307 million for the full year ended 30 June 2014, up US$96 million or 8% on a reported basis when compared to the prior comparable period (PCP). The result includes a one-off U.S. antitrust class action litigation settlement. Earnings per share (EPS) grew 11%, benefiting from current and past capital management initiatives.

15/10/2014

CSL announces new A$950m share buyback

CSL Limited (ASX:CSL) today announced a new on-market share buyback of up to A$950 million.

27/10/2014

CSL to acquire Novartis influenza vaccine business (ASX)

CSL Limited (ASX:CSL; USOTC:CSLLY) today announced that it has agreed to acquire Novartis' global influenza vaccine business for US$275 million. The business will be combined with CSL's subsidiary, bioCSL.

27/10/2014

CSL to acquire Novartis' influenza vaccine business (Media Release)

CSL Limited has today announced an agreement to acquire Novartis' global influenza vaccine business for US$275 million, which will be combined with CSL's existing vaccines and pharmaceutical subsidiary, bioCSL.

10/11/2014

CSL Limited Launches AEGIS-I, a Phase 2b Clinical Study of CSL112, a Novel Apolipoprotein A-I Infusion Therapy Designed to Rapidly Remove Cholesterol from Arteries and Stabilize Plaque

CSL Limited today announced the launch of AEGIS-I, a Phase 2b clinical study of CSL112, a novel formulation of apolipoprotein A-I (apoA-I). Administered as a short series of weekly infusions, CSL112 is designed to rapidly remove cholesterol from the arteries and stabilize lesions at risk of rupture. This represents a new approach to reduce the high incidence of early recurrent cardiovascular events in the days and weeks following a heart attack.

13/11/2014

New €350 Million Private Placement

CSL Limited (ASX:CSL; USOTC:CSLLY) today announced that on 12 November 2014 it closed a new €350 million private placement in the U.S. The private placement was foreshadowed in CSL's full year announcement in August 2014.